2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-128733S
    Phenyl acetate-d5 22705-26-6 98%
    Phenyl acetate-d5 is the deuterium labeled Phenyl acetate. Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression.
    Phenyl acetate-d5
  • HY-132833S
    1,7-Dimethyl-1H-imidazo[4,5-g]quinoxalin-2-amine-d3 1346599-36-7 98%
    1,7-Dimethyl-1H-imidazo[4,5-g]quinoxalin-2-amine-d3 is the deuterium labeled 1,7-Dimethyl-1H-imidazo[4,5-g]quinoxalin-2-amine.
    1,7-Dimethyl-1H-imidazo[4,5-g]quinoxalin-2-amine-d3
  • HY-133797S
    Cyclobenzaprine N-oxide-d3 1189877-07-3 98%
    Cyclobenzaprine N-oxide-d3 is the deuterium labeled Cyclobenzaprine N-oxide.
    Cyclobenzaprine N-oxide-d3
  • HY-135111S
    4-Desmethoxy Omeprazole-d3 1794759-05-9 98%
    4-Desmethoxy Omeprazole-d3 is the deuterium labeled 4-Desmethoxy Omeprazole. 4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Kiof 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.
    4-Desmethoxy Omeprazole-d3
  • HY-135212S
    Hydroxy ipronidazole-d3 1156508-86-9 99.89%
    Hydroxy ipronidazole-d3 is the deuterium labeled Hydroxy ipronidazole. Hydroxy ipronidazole (Ipronidazole-OH) is a metabolite of nitroimidazole antibiotics, such as ipronidazole (IPZ). Hydroxy ipronidazole may has similar mutagenic potential as the parent compound.
    Hydroxy ipronidazole-d3
  • HY-W011651S
    Carbutamide-d9 1246820-50-7 98%
    Carbutamide-d9 (BZ-55-d9) is the deuterium labeled Carbutamide. Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity.
    Carbutamide-d9
  • HY-W012722BS
    4-Methyl-2-oxopentanoic acid-d7 sodium 1795020-84-6 98%
    4-Methyl-2-oxopentanoic acid-d7 (α-Ketoisocaproic acid-d7) sodium is the deuterium labeled 4-Methyl-2-oxopentanoic acid (HY-W012722).4-Methyl-2-oxopentanoic acid is a metabolite of L-leucine and is involved in energy metabolism. 4-Methyl-2-oxopentanoic acid increases endoplasmic reticulum stress, promotes lipid accumulation in preadipocytes and insulin resistance by impairing mTOR and autophagy signaling pathways.
    4-Methyl-2-oxopentanoic acid-d7 sodium
  • HY-10288
    Melogliptin 868771-57-7 98%
    Melogliptin is a DPP-4 inhibitor. Melogliptin can be used in the research of type 2 diabetes.
    Melogliptin
  • HY-10289
    Carmegliptin 813452-18-5 98%
    Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC50 of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1, potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus.
    Carmegliptin
  • HY-10290
    MK-0674 887781-62-6 98%
    MK-0674 is a potent, orally bioavailable and selective cathepsin K inhibitor, with an IC50 of 0.4 nM, shows 1156, 1465, 11857 and 243 fold selectivity over Cat B, Cat F, Cat L and Cat S.
    MK-0674
  • HY-10555
    AMG-221 1095565-81-3 98%
    AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a Ki of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC50 of 10.1 nM in cell-based assays. AMG-221 can be used for the research of type 2 diabetes.
    AMG-221
  • HY-10568
    TC-E 5005 959705-64-7 98%
    TC-E 5005 is a potent and selective PDE10A inhibitor with IC50 values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate.
    TC-E 5005
  • HY-10575
    MK-5596 1044586-68-6 98%
    MK-5596 is an efficient, selective and orally active CB1R (IC50 = 1.0 nM, EC50 = 5.8 nM) inverse agonist. MK-5596 has weak hERG inhibitory activity. MK-5596 has strong weight loss and appetite suppression effects. MK-5596 has a certain inhibitory effect on CYP enzymes (CYP3A4: IC50 = 3.3 μM, CYP2C8: IC50 = 11 μM, CYP2C9: IC50 = 18 μM, CYP2D6: IC50 = 6 μM). MK-5596 can be used for research on conditions such as obesity.
    MK-5596
  • HY-10843
    LCI765 870194-96-0 98%
    LCI765 is an orally active and selective PPARδ agonist, with an EC50 of 0.07 nM. LCI765 can be used for the research of diseases related to energy homeostasis such as metabolic syndrome.
    LCI765
  • HY-10867
    PF-622 898235-65-9 98%
    PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant.
    PF-622
  • HY-11032
    SM-350300 902750-48-5 98%
    SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia.
    SM-350300
  • HY-11033
    DNP-60502 1007399-87-2 98%
    DNP-60502 is a phthalide derivative. DNP-60502 exhibits potent glucose production inhibitory activity by targeting key regulatory enzymes in hepatic glucose metabolism. DNP-60502 can be used for the study of type 2 diabetes.
    DNP-60502
  • HY-11073
    MK-0489 778625-65-3 98%
    MK-0489 is an orally active, highly effective, and selective MC4R agonist. MK-0489 exhibits a strong binding affinity (IC50 = 13 nM) and functional agonist activity (EC50 = 4.6 nM) at human MC4R. MK-0489 shows functional activity of 22 nM (EC50) on mouse MC4R and 1.7 μM (EC50) on mouse MC3R. MK-0489 can be used for the study of obesity.
    MK-0489
  • HY-11074
    CE-326597 870615-40-0 98%
    CE-326597 is a small molecule agonist of the cholecystokinin A receptor (CCKAR). CE-326597 occupies only the lower half of the TMD pocket and cannot mimic the crucial interaction between CCK-8 and ECL1-3. CE-326597 can be used to study metabolic diseases and gastrointestinal dysfunction.
    CE-326597
  • HY-11076
    GI 181771 305366-98-7 98%
    GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.
    GI 181771
Cat. No. 상품명 / Synonyms Application Reactivity